Diana F. Clarke, PharmD, explains how IMPAACT 2023 supported dolutegravir from birth, plus dosing tips and open questions for preterm infants.

FDA approved Lupin's generic of Firdapse for LEMS in patients 6 years and older, but a patent settlement delays US marketing until at least 2035.

CDC confirmed the first pediatric flu death of 2026-27, linked to H1N1, as early flu activity rises in 2026.

A recap of the top pediatric clinical trial results and pipeline data readouts during October 2026.

A recap of the top FDA approvals, regulatory decisions, and pipeline updates affecting pediatric care during October 2026.

With California WNV activity at a 5-year high, CHLA outlines age-based repellent and bite-prevention guidance for children.

Missed the AAP's new congenital measles guidance? This easy-to-read FAQ covers what pediatric clinicians need to know.

In PROGRESS Cohort 2, zilurgisertib reduced total HO volume vs placebo at 24 weeks in children aged 6 to 11 with FOP, with no new HO lesions.